FDA grants Orphan Drug Status for to-BBB’s lead product

25-Aug-2010 - Netherlands

to-BBB announced that the food and Drug Administration (FDA) has granted Orphan Drug Designation for to-BBB’s brain cancer lead product 2B3-101.

As a proprietary brain-targeted version of the marketed product Caelyx®/Doxil® (PEG-liposomal doxorubicin), 2B3-101 uses glutathione (GSH) to safely enhance the delivery of doxorubicin across the blood-brain barrier. The therapeutic benefit and predictable safety profile of 2B3-101 has been successfully demonstrated in pre-clinical studies and the product is ready to start clinical testing in a phase I/II study. 2B3-101 can be developed for multiple brain cancer indications and to-BBB considers development for brain metastases of breast cancer as well as glioma.

Other news from the department research and development

Most read news

More news from our other portals